
Paul V. Ward
Examiner (ID: 4583)
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1622, 1623 |
| Total Applications | 2519 |
| Issued Applications | 1801 |
| Pending Applications | 239 |
| Abandoned Applications | 539 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18013263
[patent_doc_number] => 11505545
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Anthelmintic quinoline-3-carboxamide derivatives
[patent_app_type] => utility
[patent_app_number] => 17/085880
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 141386
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 2202
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085880
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/085880 | Anthelmintic quinoline-3-carboxamide derivatives | Oct 29, 2020 | Issued |
Array
(
[id] => 20226270
[patent_doc_number] => 12414909
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-16
[patent_title] => Polysaccharide-based gelled foam
[patent_app_type] => utility
[patent_app_number] => 17/772676
[patent_app_country] => US
[patent_app_date] => 2020-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3194
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772676
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772676 | Polysaccharide-based gelled foam | Oct 26, 2020 | Issued |
Array
(
[id] => 16612117
[patent_doc_number] => 20210030770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/076081
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/076081 | LITHIUM CHOLESTEROL COMPOSITIONS, INCLUDING, BUT NOT LIMITED TO LITHIUM CHOLESTEROL SULFATE COMPOSITIONS, AND METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE AND NEUROLOGICAL DISORDERS | Oct 20, 2020 | Abandoned |
Array
(
[id] => 16749904
[patent_doc_number] => 20210101913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/076554
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10928
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076554
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/076554 | 2-OXOTHIATOLE COMPOUNDS HAVING ACTIVITY AS CPLA2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND HYPERPROLIFERATIVE DISORDERS | Oct 20, 2020 | Abandoned |
Array
(
[id] => 19186231
[patent_doc_number] => 20240165144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING INNATE IMMUNE SIGNALING PATHWAYS
[patent_app_type] => utility
[patent_app_number] => 17/769517
[patent_app_country] => US
[patent_app_date] => 2020-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769517
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769517 | COMPOSITIONS AND METHODS FOR MODULATING INNATE IMMUNE SIGNALING PATHWAYS | Oct 15, 2020 | Abandoned |
Array
(
[id] => 18056504
[patent_doc_number] => 20220387590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS
[patent_app_type] => utility
[patent_app_number] => 17/765251
[patent_app_country] => US
[patent_app_date] => 2020-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765251
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/765251 | PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS | Oct 6, 2020 | Pending |
Array
(
[id] => 17975513
[patent_doc_number] => 11492361
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => Compounds useful in HIV therapy
[patent_app_type] => utility
[patent_app_number] => 16/948873
[patent_app_country] => US
[patent_app_date] => 2020-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 53931
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948873
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/948873 | Compounds useful in HIV therapy | Oct 4, 2020 | Issued |
Array
(
[id] => 18018905
[patent_doc_number] => 20220370404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => PHARMACEUTICAL DRUG CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 17/766090
[patent_app_country] => US
[patent_app_date] => 2020-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766090
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766090 | PHARMACEUTICAL DRUG CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | Oct 1, 2020 | Pending |
Array
(
[id] => 16569071
[patent_doc_number] => 20210008077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => THERAMUTEIN MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/038457
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/038457 | Theramutein modulators | Sep 29, 2020 | Issued |
Array
(
[id] => 16581423
[patent_doc_number] => 20210015825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-21
[patent_title] => THERAMUTEIN MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/038353
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038353
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/038353 | Theramutein modulators | Sep 29, 2020 | Issued |
Array
(
[id] => 17036643
[patent_doc_number] => 20210253601
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => PYRIMIDINONES AS PI3K INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/038165
[patent_app_country] => US
[patent_app_date] => 2020-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35772
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038165
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/038165 | Pyrimidinones as PI3K inhibitors | Sep 29, 2020 | Issued |
Array
(
[id] => 18201214
[patent_doc_number] => 11583586
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-21
[patent_title] => Methods to induce targeted protein degradation through bifunctional molecules
[patent_app_type] => utility
[patent_app_number] => 17/035081
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 106
[patent_no_of_words] => 42014
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 215
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17035081
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/035081 | Methods to induce targeted protein degradation through bifunctional molecules | Sep 27, 2020 | Issued |
Array
(
[id] => 17369877
[patent_doc_number] => 20220024929
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2022-01-27
[patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
[patent_app_type] => utility
[patent_app_number] => 17/034822
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46860
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034822 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Sep 27, 2020 | Issued |
Array
(
[id] => 17369877
[patent_doc_number] => 20220024929
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2022-01-27
[patent_title] => INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
[patent_app_type] => utility
[patent_app_number] => 17/034822
[patent_app_country] => US
[patent_app_date] => 2020-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46860
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/034822 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Sep 27, 2020 | Issued |
Array
(
[id] => 17974326
[patent_doc_number] => 11491163
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => Salt form of a human histone methyltransferase EZH2 inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/032432
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 21
[patent_no_of_words] => 23486
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032432
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/032432 | Salt form of a human histone methyltransferase EZH2 inhibitor | Sep 24, 2020 | Issued |
Array
(
[id] => 18036155
[patent_doc_number] => 20220380370
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => XANTHINE CB1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/763974
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46275
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 195
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763974
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763974 | XANTHINE CB1 INHIBITORS | Sep 24, 2020 | Abandoned |
Array
(
[id] => 18094642
[patent_doc_number] => 20220412983
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => LUMINESCENT COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/763168
[patent_app_country] => US
[patent_app_date] => 2020-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763168
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763168 | LUMINESCENT COMPOUNDS | Sep 23, 2020 | Pending |
Array
(
[id] => 16710303
[patent_doc_number] => 20210077450
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => TREATMENT FOR OBESITY
[patent_app_type] => utility
[patent_app_number] => 17/028674
[patent_app_country] => US
[patent_app_date] => 2020-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17028674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/028674 | Treatment for obesity | Sep 21, 2020 | Issued |
Array
(
[id] => 18085499
[patent_doc_number] => 11535616
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-27
[patent_title] => Histone demethylase inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/026763
[patent_app_country] => US
[patent_app_date] => 2020-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29229
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026763
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/026763 | Histone demethylase inhibitors | Sep 20, 2020 | Issued |
Array
(
[id] => 18097839
[patent_doc_number] => 20220416180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => O^C^N^N-TYPE TETRADENTATE PLATINUM (II) COMPLEX, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/776978
[patent_app_country] => US
[patent_app_date] => 2020-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3758
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776978
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776978 | O^C^N^N-type tetradentate platinum (II) complex, preparation method therefor, and application thereof | Sep 18, 2020 | Issued |